NeuroMetrix, Inc.
NUROHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0M | $5.9M | $8.3M | $8.3M | $7.4M | $9.3M |
| Operating income | −$8.8M | −$7.2M | −$4.7M | −$2.3M | −$2.1M | −$11.5M |
| Net income | −$7.8M | −$6.5M | −$4.4M | −$2.3M | −$2.1M | −$3.8M |
| Total assets | $15.3M | $21.4M | $24.7M | $24.9M | $8.0M | $6.9M |
| Total liabilities | $1.0M | $1.3M | $1.3M | $1.7M | $2.7M | $4.4M |
| Equity | $14.3M | $20.1M | $23.4M | $23.2M | $5.2M | $2.5M |
| EPS (diluted) | $-3.96 | $-6.27 | $-4.97 | $-0.45 | $-0.69 | $-3.90 |
| Shares out. | 2.0M | 7.8M | 7.0M | 3.8M | 1.4M | 7.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −289.6%
- Net margin
- −257.4%
- Return on equity
- −54.5%
- Return on assets
- −50.9%
- Return on capital (ROCE)
- −61.4%
- Liabilities / assets
- 6.6%
- Debt / equity
- 0.07×
- Book value / share
- $7.20
- Revenue growth (YoY)
- −48.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -29.37distress
- Accruals / assets
- −4.4%clean
- Beneish M-Score
- -3.63normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 16, 2007
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Radoff Bradley LouisPassive (13G)Aug 13, 2025
- Fields Ephraim GActivist (13D)Dec 19, 2024
- Rs Fund LpActivist (13D)Apr 1, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Horowitz JoshuaDirector | May 1, 2025 | D | 29,807 | — |
| Goodman DavidDirector | May 1, 2025 | D | 7,602 | — |
| Van Avermaete DavidDirector | May 1, 2025 | D | 7,601 | — |
| Higgins Thomas TOfficer — Senior Vice President, CFO | May 1, 2025 | D | 11,840 | — |
| Katz Nancy EDirector | May 1, 2025 | D | 7,602 | — |
| Gozani ShaiOfficer — President and CEO | May 1, 2025 | D | 15,466 | — |
| Higgins Thomas TDirector | Apr 1, 2025 | Option exercise | 469 | $4.41 |
| Gozani ShaiDirector | Apr 1, 2025 | Option exercise | 625 | $4.41 |
| Higgins Thomas TDirector | Feb 2, 2025 | Option exercise | 498 | $4.31 |
| Gozani ShaiDirector | Feb 2, 2025 | Option exercise | 636 | $4.31 |
| Higgins Thomas TDirector | Jan 1, 2025 | Option exercise | 469 | $3.97 |
| Gozani ShaiDirector | Jan 1, 2025 | Option exercise | 625 | $3.97 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Apr 30, 2025 | 161 | 1.0 | -92.9% |
| Apr 15, 2025 | 2,269 | 1.0 | +249.6% |
| Mar 31, 2025 | 649 | 1.0 | -58.1% |
| Mar 14, 2025 | 1,548 | 1.0 | -37.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventMay 2, 2025
- Shareholder voteMar 25, 2025
- Entered a material agreementJan 23, 2025
- Director / officer changeDec 30, 2024
- Entered a material agreement · Regulation FD disclosureDec 17, 2024
- Results of operationsNov 5, 2024
- Results of operationsAug 6, 2024
- Shareholder voteMay 1, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.